Asthma drug by GSK given green light for use in China
Pharmaceutical company GSK announced on Wednesday that its novel targeted biological agent Nucala has been approved in China to treat a type of severe asthma.
Nucala will be used for maintenance treatment of severe eosinophilic asthma (SEA) in adults and adolescents aged 12 and above.
SEA accounts for the largest number of severe asthma cases.
The drug is expected to provide an advanced disease management approach for millions of Chinese patients suffering from this respiratory disease, said the company.
GSK said the approval was given following an independent, Phase III clinical trial involving Chinese patients that yielded positive results.
There are roughly 46 million adults in China who suffer from asthma, with about 6 percent suffering from severe asthma.
- Consumer complaints rise over AI customer service failures
- Zhejiang authorities probe death of child in hospital
- China moves to reduce childcare costs
- High-altitude discovery sheds light on early settlers of Qinghai-Tibet Plateau
- Beijing seminar studies legal systems of Francophone countries
- Approved private vehicles now permitted direct access to Hong Kong
